Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

May 26, 2017

News Industry News

Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack

February 18, 2016

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Industry News

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013

News Industry News

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

June 26, 2012

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Industry News

Health Canada approves BRILINTA (ticagrelor tablets)

June 01, 2011

Advertisement

AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle from That Lot

Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

Health Canada approves BRILINTA (ticagrelor tablets)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content